These include: Diuretics (furosemide, hydrochlorothiazide) which can exacerbate volume depletion ACE inhibitors or ARBs (lisinopril, losartan) which may cause acute kidney injury when combined with dehydration NSAIDs (ibuprofen, naproxen) which reduce kidney blood flow SGLT2 inhibitors (empagliflozin, dapagliflozin) which cause osmotic diuresis, though these medications have proven renal and cardiovascular benefits and should not be discontinued without medical advice Advanced age (over 65 years) and cardiovascular disease also increase vulnerability to kidney injury
But here's the thing: once you understand the basics, it becomes second nature
Tirzepatide Research Profile: Dual GIP / GLP-1 Interest Tirzepatide is commonly discussed in research literature as a dual GIP and GLP-1 receptor agonist
If you can tolerate weekly dosing, the evidence strongly supports sticking with it
If Tirzepatide is a good fit, the clinic designs a personalized plan that typically includes a starting dose of the injection with a schedule for gradual adjustment, education on proper injection technique and safe handling of the medication, and a realistic nutrition strategy focused on balanced meals with adequate protein, fiber, and hydration
Curious how retatrutide compares with specific GLP-1s
